DE-LYCRA
27.7.2021 11:02:09 CEST | Business Wire | Press release
The LYCRA Company , a global leader in developing innovative solutions for the textile, apparel, and personal care industries, today introduced a breakthrough LYCRA® FitSense™ technology innovation that reduces or eliminates the need for bra foam. This patent-pending bra cup application can be used in intimate apparel such as traditional wired, non-wired or unlined bras (including bralettes and sport bras), plus activewear and swimwear.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005390/en/
LYCRA® FitSense™ technology is a water-based, solvent-free dispersion that is comprised of the same molecule as LYCRA® fiber. The dispersion is screen-printed directly onto the bra fabric, increasing the power of the fabric in precise areas. The power increase in the bra cup effectively reduces nipple protrusion while providing symmetrical support, shaping and lift for the bustline—reducing or eliminating the need for sewn-in panels or insertable pads.
Zones of support can be applied to the bottom and sides of the bra cup for shaping, as well as the wing for maximum comfort and smoothing. LYCRA® FitSense™ technology also can be applied between fabric layers in the bra cup to mask nipple protrusion while retaining the original fabric aesthetics.
“With LYCRA® FitSense™ technology, the print does the work of the pad and enables brands to build a better bra for all sizes, styles and silhouettes—a true breakthrough development,” said Melissa Stewart, global technology director-R&D materials innovations. “With this new innovation, women have more choices in bras that provide functionality, style and comfort.”
Bras can be rigid, bulky, and hot, with multiple components and structures creating an uncomfortable, restrictive wearing experience. LYCRA® FitSense™ technology can be used to design functional bras that are lighter, thinner, and more breathable, without sacrificing modesty, all-day comfort, durability, support or shaping. And unlike polyurethane foam—which discolors and can move around or even get lost in the wash—LYCRA® FitSense™ technology is built into the garment and is highly durable to machine washing and regular wear. Further, in swimwear applications, the technology provides chlorine resistance and fast drying benefits versus foams and dual fabric layers.
LYCRA® FitSense™ technology offers intimate apparel makers versatility to create intentional design aesthetics by incorporating delicate patterns and artistic details that align with their brand identities. “Designs and colors can be easily customized to deliver on-trend fashion cues—from feminine, lacelike designs to sporty geometric shapes—that satisfy all tastes,” said Stewart. “With LYCRA® FitSense™ technology, a designer’s imagination is the only creative limitation.”
LYCRA® FitSense™ technology, which achieved the ECO PASSPORT by OEKO-TEX® sustainability certification, is applied using standard screen-printing processes, eliminating the need for specialty equipment or major supply chain upgrades. The LYCRA Company provides technical guidance to enable brands, retailers, and garment makers to easily access this innovation.
For more information, download our white paper on the LYCRA FitSense™ technology and screen-printed bra cup application.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA® , LYCRA HyFit® , LYCRA® T400® , COOLMAX® , THERMOLITE® , ELASPAN® , SUPPLEX® , and TACTEL® . The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com .
LYCRA® FitSense™ is a trademark of The LYCRA Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005390/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom